People with multiple sclerosis (MS) engage in significantly more sedentary behaviors — activities like watching TV or using a…
Articles by Steve Bryson, PhD
Extending Tysabri (natalizumab) dosing intervals based on the drug’s blood levels was as effective at controlling disease activity in…
Nearly two years of treatment with Vumerity (diroximel fumarate) significantly reduced relapse rates by more than 80% in people…
iConquerMS, a research initiative where people affected by multiple sclerosis (MS) contribute their health data and ideas, is…
Measuring the amount of specific antibody clumps in the blood helped distinguish people with multiple sclerosis (MS) from healthy…
A noninvasive brain stimulation technique called transcranial direct current stimulation (tDCS) can significantly improve walking abilities in people with…
Using a vaccine against the Epstein-Barr virus (EBV) to prevent the development of multiple sclerosis (MS) is highly likely…
Adhering to a low-fat diet for three months was found to significantly ease fatigue among people with multiple sclerosis…
ChariotMS, the world’s first clinical trial to test whether Mavenclad (cladribine) can slow the worsening of upper limb function…
Women with multiple sclerosis (MS) have significantly lower relapse rates after entering menopause, but disability levels increase significantly in…
Two non-pharmacological rehabilitation approaches — one using a computer program designed to improve working memory and the other involving standardized…
People with multiple sclerosis (MS) who receive vaccines against influenza — commonly known as flu shots — as well…
Octave Bioscience plans to test its precision care program in an observational, real-world study with people with multiple…
Innodem Neurosciences has signed a multi-year agreement with Novartis Canada to continue developing Innodem’s digital biomarker eye-tracking technology,…
Levels of GFAP protein in the blood — a marker of damage to support cells in the brain — were…
Pilates exercise with a relaxation technique improved walking abilities and self-awareness among people with multiple sclerosis (MS), according to…
People with multiple sclerosis (MS) with a rapid decline in walking abilities were more likely to be older when…
Neurologists in the U.S. are largely satisfied with current treatment options for relapsing-remitting multiple sclerosis (RRMS), but opportunities remain…
Vitamin D reduced the signs of inflammation and nerve damage in a rat model of progressive multiple sclerosis (MS),…
Neurofilament light chain (NfL) protein levels can be used to assess neurodegeneration in children and adolescents with neurological disease, including…
Treatment with Tecfidera (dimethyl fumarate) provides a similar long-term benefit for Black and Hispanic people with multiple sclerosis…
NX210c, an investigational therapy for multiple sclerosis (MS) and other neurodegenerative diseases from Axoltis Pharma, will have its…
People with multiple sclerosis (MS) living in the U.K. who identified as South Asian reported their first symptoms at…
Elevated blood levels of neurofilament light chain (NfL), a marker of nerve damage, are associated with long-term disability progression in…
Mavenclad (cladribine) is equally as effective as Gilenya (fingolimod) in reducing relapse rates among multiple sclerosis (MS)…
Outcomes are better for people with relapsing-remitting multiple sclerosis (RRMS) initially treated with higher efficacy disease-modifying therapies (DMTs)…
Aubagio (teriflunomide), an approved therapy for relapsing forms of multiple sclerosis (MS), works by shifting the balance between…
Researchers identified a genetic variant that associated with faster multiple sclerosis (MS) progression and greater brain tissue damage, according…
The government of Canada soon will provide new income benefits designed to help Canadians living with a disability — including…
Nearly 80% of adults with highly active relapsing-remitting multiple sclerosis (RRMS) were free of relapses or confirmed disability worsening…